Quick Answer
CASI Pharmaceuticals, Inc. reported Operating Income of -$39.62 million for fiscal year 2024.
CASI Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$39.62M | -58.0% |
| 2023 | -$25.08M | +26.3% |
| 2022 | -$34.03M | +18.0% |
| 2021 | -$41.52M | +21.3% |
| 2020 | -$52.78M | — |
- CASI Pharmaceuticals, Inc. showed a decrease of -58.0% in Operating Income compared to the prior fiscal year.
- Over the 2020–2024 period, CASI Pharmaceuticals, Inc.’s operating income has grown by 24.9% (from -$52.78 million to -$39.62 million).
- The most recent figure is from CASI Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 20-F), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: